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INVITED ARTICLE
Chronic Kidney Disease – Mineral and Bone Disorder 
(CKD-MBD) begins early in the course of kidney disease 
and is under-diagnosed. Decreased vitamin D receptor 
(VDR) activation is a major pathophysiologic factor in the 
development of secondary hyperparathyroidism (SHPT) 
and contributes to CKD morbidity and mortality. In con-
trast, VDR inactivation influences bone and cardiovascular 
disease (CVD) progression and mortality. Some data sug-
gest that treatment choices influence patient survival. These 
data underline the need for early assessment and clear man-
agement strategies. It is important to identify patients at in-
creased risk for a poor prognosis and to better understand 
whether early treatment will benefit these patients.
Observational data indicate that there is a close in-
ter-relationship between progressive renal dysfunction 
in CKD patients, CVD, and mortality1. Causes of mor-
tality in patients with even moderate kidney dysfunc-
tion (measured by estimated glomerular filtration rates, 
[GFR]) are commonly associated with cardiovascular-re-
lated events1. Data from a 5-year prospective longitudinal 
study involving more than 27,000 patients in the United 
States have shown that CKD patients are more likely to 
die than develop end stage renal disease (ESRD), and that 
congestive heart failure (CHF) and coronary artery dis-
ease were both more prevalent than haemodialysis in this 
patient population2. 
CKD is characterized by progressive kidney dysfunc-
tion, manifest at later stages through notably diminished 
GFR, endocrine dysfunction, extra-skeletal calcification, 
and mineral metabolism disorders3. Reduced vitamin D 
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receptor (VDR) activation may occur early in the course 
of CKD as a consequence of vitamin D deficiency and 
CKD-associated mineral bone disease (MBD), effects 
frequently appearing before a significant rise in para-
thyroid hormone (PTH) levels4. VDR activators or ago-
nists effectively lower elevated PTH levels and provide 
improved patient survival compared with untreated pa-
tients5. VDR activators initiate signaling through ligand 
binding to the ubiquitously-present VDR, followed by 
activation of downstream endocrine, paracrine, and/or 
autocrine loops to maintain homeostasis in the kidney, 
bone, immune, and cardiovascular systems6. The con-
tinued development of newer VDR activators has led to 
further improvement in VDR tissue selectivity and safety, 
showing equivalent or better PTH-reducing effects, and 
expanded clinical impact on cardiovascular endpoints 
beyond reducing PTH levels while minimizing effects on 
calcium and phosphorus absorption in the intestine7-9. 
VDR Activation in CKD and Cardiovascular Disease 
Epidemiology
It has been shown that in the presence of altered kid-
ney function, 50% of the patients with vitamin D insuf-
ficiency and thus decreased VDR activation will have 
normal PTH levels4. This observation is more evident for 
those with lower levels of GFR. Additionally it is well 
known that the rate of cardiovascular events, as well as 
mortality rate, increase as GFR declines1. In a recent 
study, an increased relative risk was observed in hemo-
dialysis dependent patients with low levels of calcitriol 
(1,25(OH) vit. D), which was ameliorated by the treat-
ment with VDR activators10. Similarly, in a well designed 
retrospective study which included more than 40,000 he-
modialysis patients, the protective action of VDR activa-
tors was revealed11. These patients showed approximately 
20% better total and cardiovascular survival over those 
who did not follow VDR activator treatment11. Another 
impressive finding of this study was the sustained advan-
tage of VDR activation independent of age, gender, race, 
calcium, phosphorus and PTH levels. Following the same 
pattern, other ethnic observational studies have shown a 
clear survival advantage in favor of VDR activators in 
hemodialysis patients with elevated PTH levels12. 
 On the other hand, other statistical approaches of the 
same data from the DOPPS study have shown no benefit 
for those under VDR activators treatment13. According to 
these authors, inevitably, a randomized controlled trial of 
vitamin D in hemodialysis patients is needed. Converse-
ly, in a large number of patients who were followed for a 
period of a few years, it has been seen a dose dependent 
advantage for those receiving paricalcitol treatment14. Fi-
nally, even per os administration of VDR activators has 
been proven beneficial in hemodialysis patients, and has 
been associated with improved cardiovascular, infec-
tious, neoplastic and overall mortality15.
Interestingly, in a study sample of more than 3,000 
people from the general population, who were scheduled 
for coronary angioplasty, the authors observed a much 
higher all cause (HR= 2.08) and cardiovascular mortality 
(HR= 1.53) for those with lower levels of vitamin D16. 
All things considered, VDR activation seems to play 
a key role in human survival, even though solid evidence 
will be provided by future randomized studies. 
The Role of VDR Activation on SHPT and 
Cardiovascular Outcome
For many years, the administration of calcitriol has 
been the mainstay of treatment for SHPT in CKD pa-
tients17. However, several novel findings and issues have 
substantially influenced nephrologists` attitudes towards 
VDRAs administration in recent years. High serum cal-
cium (Ca) and phosphate (P) levels have been convinc-
ingly associated with reduced survival in CKD patients18. 
Moreover, Tonelli et al investigated the impact upon 
outcome of even small increases in serum P levels at the 
time of an acute myocardial infarction. They found an 
association of higher - but still within the normal range 
- P levels with the occurrence secondary cardiovascular 
events in non-dialysis patients19. VC may result from 
high dosages of vitamin D administration, as seen in sev-
eral animal models with renal insufficiency19. Moreover, 
some evidence exists that previous calcitriol treatment in 
humans with advanced CKD is one of the VC promoting 
factors20. 
There is consistent observational data available that 
the administration of active vitamin D in dialysis patients 
and patients with advanced renal failure is associated 
with improved survival, irrespective of underlying P and 
Ca levels21. This survival improvement may be attrib-
utable to both the traditional bone and mineral actions 
of vitamin D as well as to the pleiotropic actions. As a 
consequence of these divergent statements, and since 
prospective, randomized data are missing, nephrologists 
might well get “lost in translation” if they try to transfer 
all the available experimental and observational data into 
every-day patient care. Currently, the bedside treatment 
decision for SHPT in CKD is even more complex: In the 
beginning of active vitamin D treatment in ESRD there 
used to be only the simple question: to give calcitriol or 
not to give calcitriol. In contrast, nowadays, there are 
several so-called vitamin D receptor activators (VDRAs) 
available: 1,25-dihydroxy-22-oxavitamin D3 (22-oxa-
calcitriol, OCT), 1,25-dihydroxy-19-norvitamin D2 (19-
norD2, paricalcitol), 1α-hydroxyvitamin D2 (1αOHD2). 
These novel alternative agents all claim to imitate the 
typical calcitriol action, i.e. reduction of SHPT. On the 
other hand, they deny being comparable to vitamin D re-
garding some other less desirable actions such as induc-
tion of hypercalcaemia or hyperphosphataemia17. 
Numerous observational studies show a clinical ad-
vantage for VDR activator therapy. To date, no studies 
have demonstrated increased mortality in patients receiv-
ing VDR activator therapy. Intravenous VDR activator 
therapy confers a survival advantage in patients on di-
alysis17. Kalantar-Zadeh and coworkers22 have shown an 
association between any time-varying administered dose 
of paricalcitol and relative risk of death in over 58,000 
maintenance HD patients over 2 years. Moreover, Wolf 
and colleagues23 have shown in the ArMORR prospec-
tive, cross-sectional studies that 1,25-D and 25D defi-
ciencies in incident HD patients are associated with an 
increased mortality risk that is reduced following the 
introduction of VDR activator therapy given in conjunc-
tion with dialysis. The association of improved survival 
with VDR activation therapy can already be observed in 
patients with moderate renal impairment. VDR activators 
directly affect cardiovascular outcomes, apparently by 
mechanisms independent of SHPT. These include effects 
on the immune system, RAS, and development of athero-
sclerosis, cardiac remodelling, and LVH. 
Conclusions
A mounting body of evidence indicates that a defi-
ciency in vitamin D and VDR activation play a crucial 
role in CKD, as well as cardiovascular outcomes in both 
CKD patients and the general population. VDR activa-
tion pathways mediate widespread activities that include 
the maintenance of and interrelated effects between car-
diovascular and renal integrity. Preclinical and clinical 
data continue to support that when VDR activators are 
used at clinically relevant doses, an efficacious response 
is shown with minimal risk of vascular calcification. Ad-
verse effects such as hypercalcemia and phosphatemia are 
further lessened with the use of selective VDR activators. 
In addition, selective VDR activation differentially exerts 
a number of ameliorative effects on parameters outside 
COZZOLINO M
HIPPOKRATIA 2010, 1, 1 9
of cardiovascular and renal disease, such as immunologic 
effects. Some data now suggest that recognition of CKD 
and cardiovascular interrelated effects requires cumula-
tive assessment of patient health for the appropriate se-
lection of treatments that may influence patient survival. 
These data underline the need for early identification of 
vitamin D deficiency and clear management strategies. 
Data continue to accrue to help define the many poten-
tially beneficial physiologic effects of VDR activators in 
CKD patients with CKD or CVD. 
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